Immix Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview

Reuters11-08

<a href="https://laohu8.com/S/IMMX">Immix Biopharma</a> Inc <immx.oq> expected to post a loss of 17 cents a share - Earnings Preview </immx.oq>

Immix Biopharma Inc IMMX.OQ IMMX.O is expected to report results on November 10 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Immix Biopharma Inc is for a loss of 17 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts had fallen by about 18.7% in the last three months.
Wall Street's median 12-month price target for Immix Biopharma Inc is $8.00, about 60.6% above its last closing price of $3.15

This summary was machine generated November 7 at 23:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581837040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-08 07:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581837040","market":"fut","top_or_hot":-1,"title":"Immix Biopharma Inc  expected to post a loss of 17 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/IMMX\">Immix Biopharma</a> Inc <immx.oq> expected to post a loss of 17 cents a share - Earnings Preview </immx.oq></title></head><body><ul><li><p>Immix Biopharma Inc <span>IMMX.OQ</span> <span>IMMX.O</span> is expected to  report results on November 10 (estimated) for the period ending December 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Immix Biopharma Inc is for a loss of 17 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The mean earnings estimate of analysts had fallen by about 18.7% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Immix Biopharma Inc is $8.00, about 60.6% above its last closing price of $3.15</p></li></ul><p>This summary was machine generated November 7 at 23:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma Inc  expected to post a loss of 17 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma Inc  expected to post a loss of 17 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-08 07:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/IMMX\">Immix Biopharma</a> Inc <immx.oq> expected to post a loss of 17 cents a share - Earnings Preview </immx.oq></title></head><body><ul><li><p>Immix Biopharma Inc <span>IMMX.OQ</span> <span>IMMX.O</span> is expected to  report results on November 10 (estimated) for the period ending December 31 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Immix Biopharma Inc is for a loss of 17 cents per share. </p></li><li><p>The one available analyst rating on the shares is \"buy\".  </p></li><li><p>The mean earnings estimate of analysts had fallen by about 18.7% in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Immix Biopharma Inc is $8.00, about 60.6% above its last closing price of $3.15</p></li></ul><p>This summary was machine generated November 7 at 23:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ34C:1","article_id":"2581837040","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581837040","pubTimestamp":1762559524,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immix Biopharma Inc  expected to post a loss of17cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to  report results on November 10 (estimated) for the period ending Dec","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMMX":"Immix Biopharma, Inc"},"translate_title":"Immix Biopharma Inc预计每股亏损17美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMMX":0.9},"content_text":"Immix Biopharma Inc  expected to post a loss of 17 cents a share - Earnings Preview Immix Biopharma Inc IMMX.OQ IMMX.O is expected to  report results on November 10 (estimated) for the period ending December 31 2025LSEG's mean analyst estimate for Immix Biopharma Inc is for a loss of 17 cents per share. The one available analyst rating on the shares is \"buy\".  The mean earnings estimate of analysts had fallen by about 18.7% in the last three months. Wall Street's median 12-month price target for Immix Biopharma Inc is $8.00, about 60.6% above its last closing price of $3.15This summary was machine generated November 7 at 23:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581837040","isCrawlerRequest":true}